is hers glp 1 fda approved GLP-1 Safety Check Hims & Hers stock crashes

Across the market as of April 2026, monthly totals commonly sit between roughly $200 and $700 or more, which is why a headline price rarely tells the whole story

This scientific uncertainty directly impacts commercial interest, as developing a drug for a fragmented and unpredictable subpopulation within an already rare disease is a high-risk investment

GLP-1 receptor agonists may be appropriate second-line agents after metformin or even first-line in patients with established cardiovascular disease, chronic kidney disease, or when weight management is a priority

Most likely, your doctor will start you on metformin first because its hard to change clinical inertia